Bsense Bio Therapeutics
Tel Aviv, Israel· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Dual‑target small molecules for non‑opioid pain, tinnitus and itch relief.
PainTinnitusPruritus
Technology Platform
A single‑molecule dual modulator that inhibits TRPV1 and activates Kv7.2/3 ion channels, providing selective potency in co‑localized sensory neurons.
Opportunities
Successful Phase I data could unlock partnerships with major pharma for co‑development and broaden the platform to additional sensory disorders.
Risk Factors
Early‑stage clinical translation risk and limited funding could delay progression of multiple programs.
Competitive Landscape
Bsense’s dual‑target ion‑channel approach differentiates it from conventional analgesics and single‑target TRPV1 antagonists, offering a novel safety and efficacy profile.